Roche has reported phase 2 results with a dual GIP/GLP-1 agonist obesity candidate, achieving weight loss of up to 22.5%, as it prepares for a phase 3 programme. The phase 2 trial of CT-388, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results